At Myriad, we use state-of-the art technologies including DNA sequencing, RNA analysis and proteomics to innovate and create the next generation of breakthrough diagnostics. Our talented scientists are working in collaboration with universities, biotech and pharmaceutical companies, and government agencies to accelerate the pace of innovation for patients worldwide. This approach affords us a diversity of perspectives as well as access to cutting-edge science regardless of where it resides.
Myriad has invested over $377 million in research over the past five years. Click here to download our latest corporate fact sheet: https://myriad.com/about-myriad/inside-myriad/myriad-fact-sheet/
August 11, 2022